Biolyst › OGNCash runway
Cash generating
Organon & Co. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects on October 15, 2026. There are 2 upcoming events on record.
Organon & Co. generates cash from operations, so a burn-based runway figure does not apply.
Across 503 concluded trials, 94% reached completion rather than being terminated or withdrawn.
Track OGN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open OGN in the tracker
Recent history
Date Event Type Phase
July 31, 2026
8-K filed: Reg FD disclosure Filing
—
July 17, 2026
8-K filed: Other event Filing
—
June 11, 2026
8-K filed: Leadership change Corporate
—
April 30, 2026
Quarterly results filed (8-K) Earnings
—
April 27, 2026
8-K filed: Material agreement, Leadership change, Reg FD disclosure Corporate
—
February 20, 2026
8-K filed: Other event Filing
—
February 12, 2026
Quarterly results filed (8-K) Earnings
—
November 10, 2025
Quarterly results filed (8-K) Earnings
—
November 7, 2025
8-K filed: Leadership change Corporate
—
October 30, 2025
8-K/A filed: Leadership change Corporate
—
October 27, 2025
8-K filed: Leadership change, Other event Corporate
—
August 5, 2025
Quarterly results filed (8-K) Earnings
—
June 12, 2025
8-K filed: Leadership change Corporate
—
May 28, 2025
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain Trial Milestone
Phase 2
May 27, 2025
8-K filed: Other event Filing
—
May 1, 2025
Quarterly results filed (8-K) Earnings
—
April 15, 2025
8-K filed: Leadership change, Reg FD disclosure Corporate
—
December 30, 2024
A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060) Trial Milestone
Phase 3
September 4, 2024
Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients Trial Milestone
Phase 4
February 29, 2024
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis Trial Milestone
Phase 3
January 12, 2024
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive Trial Milestone
Phase 3
June 30, 2023
A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region Trial Milestone
Phase 4
May 18, 2023
A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis Trial Milestone
Phase 4
March 30, 2023
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults Trial Milestone
Phase 3
February 3, 2023
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) Trial Milestone
Phase 3
August 24, 2022
Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis Trial Milestone
Phase 2
April 6, 2021
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) Trial Milestone
Phase 3
March 17, 2021
Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439) Trial Milestone
Phase 3
May 26, 2020
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) Trial Milestone
Phase 3
May 13, 2020
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) Trial Milestone
Phase 3
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.